Bajaj Healthcare Launches Drug To Cure Black Fungus In COVID Patients

Giving relief amidst mounting Mucormycosis cases, Bajaj Healthcare on May 28 launched a drug to treat the black fungus infection in the COVID-19 patients. Named Posaconazole API, the anti-fungal drug has been granted regulatory approval by the Food and Drugs Administration (FDA) Gandhinagar, Gujarat. Meanwhile, the company aims at starting commercial production as early as in June first week for the both domestic and international market.